[go: up one dir, main page]

DK2851368T3 - Kompleks-forbindelser af germanium, fremgangsmåder til fremstilling deraf, og lægemidler - Google Patents

Kompleks-forbindelser af germanium, fremgangsmåder til fremstilling deraf, og lægemidler Download PDF

Info

Publication number
DK2851368T3
DK2851368T3 DK12876796.9T DK12876796T DK2851368T3 DK 2851368 T3 DK2851368 T3 DK 2851368T3 DK 12876796 T DK12876796 T DK 12876796T DK 2851368 T3 DK2851368 T3 DK 2851368T3
Authority
DK
Denmark
Prior art keywords
germanium
guanine
complex compound
derivative
acyclovir
Prior art date
Application number
DK12876796.9T
Other languages
English (en)
Inventor
Alexandr Dmitrievich Isaev
Igor Valerievich Ambrosov
Tamaz Omarovich Manasherov
Svetlana Konstantinovna Matelo
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostyu Wds Farma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostyu Wds Farma filed Critical Obschestvo S Ogranichennoi Otvetstvennostyu Wds Farma
Application granted granted Critical
Publication of DK2851368T3 publication Critical patent/DK2851368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/30—Germanium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Kompleks-forbindelser af germanium med den generelle strukturformel (I):
(I) hvor AD er et nitrogenholdigt purinbasederivat med en antiviral aktivitet; CA er en hydroxycarboxylsyre; AA er en aminosyre valgt fra a-aminosyrer, hvor x = 1-2, y = 2-4, og z = 0-2, og hvor alle AD'er i kompleks-forbindelsen er de samme eller forskellige, alle CA'er i kompleks-forbindelsen er de samme eller forskellige, og alle AA'er i kompleks-forbindelsen er de samme eller forskellige.
2. Kompeks-forbindelse ifølge krav 1, hvor AD'et er et derivat af guanin eller adenin.
3. Kompleks-forbindelse ifølge krav 2, hvor guaninderivatet er valgt fra gruppen bestående af acyclovir (9-[(2-hydroxyethoxy)methyl]guanin), valacyclovir (2-(guanin-9-ylmethoxy)ethyl L-valinether), gancyclovir (9-[(l,3-dihydroxy-2-propoxy)methyl]guanin), pencyclovir (9-[4-hydroxy-3- (hydroxymethyl)butyl]guanin) eller blandinger deraf.
4. Kompleks-forbindelse ifølge krav 2, hvor adeninderivatet er valgt til at være vidarabin (9-p-D-arabinofuranosyladenin).
5. Kompleks-forbindelse ifølge krav 1, hvor aminosyren AA er valgt fra gruppen bestående af arginin, glycin, lysin, threonin eller blandinger deraf.
6. Kompleks-forbindelse ifølge krav 1, hvor hydroxycarboxylsyren CA er valgt fra gruppen bestående af citronsyre, mælkesyre, æblesyre eller blandinger deraf.
7. Fremgangsmåde til fremstilling af kompleks-forbindelser af germanium ifølge et hvilket som helst af kravene 1 til 6, omfattende trinnene: (a) at blande germaniumdioxid med vand for at tilvejebringe en vandig opløsning eller en vandig opslæmning; (b) at tilsætte til den vandige opløsning eller den vandige opslæmning:
(i) mindst en forbindelse der er et nitrogenholdigt purinbasederivat med en antiviral aktivitet, mindst en hydroxycarboxylsyre, og mindst en aminosyre; eller (ii) mindst en forbindelse der er et nitrogenholdigt purinbasederivat med en antiviral aktivitet og mindst en hydroxycarboxylsyre, hvor komponenterne tilsættes i en hvilken som helst rækkefølge; (c) at opvarme den således opnåede blanding under omrøring ved en temperatur på 40-100°C i 3-14 timer; (d) at filtrere den resulterende opløsning; og (e) at fjerne vand fra opløsningen for at opnå en kompleks-forbindelse.
8. Fremgangsmåde ifølge krav 7, hvor opvarmning udføres ved en temperatur på 80-100°C i 5-12 timer, fortrinsvis ved en temperatur på 85-100°C i 6-8 timer.
9. Fremgangsmåde ifølge krav 7, hvor opvarmning udføres under omrøring indtil der dannes en klar opløsning.
10. Fremgangsmåde ifølge krav 7, hvor det nitrogenholdige purinbasederivat med en antiviral aktivitet er et guanin- og/eller adeninderivat, og hvor guaninderivatet fortrinsvis er en forbindelse valgt fra gruppen bestående af acyclovir (9-[(2-hydroxyethoxy)methyl]guanin), valacyclovir (2-(guanin-9-ylmethoxy)ethyl L-valinether), gancyclovir (9-[(l,3-dihydroxy-2-propoxy)methyl]guanin), pencyclovir (9-[4-hydroxy-3-(hydroxymethyl)butyl]guanin) eller blandinger deraf, og adeninderivatet fortrinsvis er vidarabin (9-p-D-arabinofuranosyladenin).
11. Fremgangsmåde ifølge krav 7, hvor aminosyren er arginin, glycin, lysin, threonin eller blandinger deraf, og/eller hydroxycarboxylsyren er citronsyre, mælkesyre, æblesyre eller blandinger deraf.
12. Kompleks-forbindelse af germanium som defineret ifølge et hvilket som helst af kravene 1 til 6 til anvendelse som et immunstimulerende middel.
13. Kompleks-forbindelse af germanium som defineret ifølge et hvilket som helst af kravene 1 til 6 til anvendelse til behandling og/eller forebyggelse af en virussygdom.
14. Kompleks-forbindelse af germanium som defineret ifølge et hvilket som helst af kravene 1 til 6 til anvendelse ifølge krav 13, hvor virussygdommen er forårsaget af herpes virus, fortrinsvis herpes virus type 1 eller type 2.
DK12876796.9T 2012-05-16 2012-11-01 Kompleks-forbindelser af germanium, fremgangsmåder til fremstilling deraf, og lægemidler DK2851368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012120329/04A RU2487878C1 (ru) 2012-05-16 2012-05-16 Комплексные соединения германия с производными азотистых оснований пуринового ряда, способы их получения и содержащие их лекарственные средства
PCT/RU2012/000897 WO2013172732A1 (ru) 2012-05-16 2012-11-01 Комплексные соединения германия, способы их получения и лекарственные средства

Publications (1)

Publication Number Publication Date
DK2851368T3 true DK2851368T3 (da) 2019-02-25

Family

ID=48791166

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12876796.9T DK2851368T3 (da) 2012-05-16 2012-11-01 Kompleks-forbindelser af germanium, fremgangsmåder til fremstilling deraf, og lægemidler

Country Status (16)

Country Link
US (1) US9745337B2 (da)
EP (1) EP2851368B1 (da)
JP (1) JP5993088B2 (da)
KR (1) KR101717280B1 (da)
CN (1) CN104302651B (da)
AU (1) AU2012380376B2 (da)
BR (1) BR112014027919B1 (da)
CA (1) CA2873390C (da)
DK (1) DK2851368T3 (da)
ES (1) ES2710915T3 (da)
IN (1) IN2014DN09234A (da)
PL (1) PL2851368T3 (da)
PT (1) PT2851368T (da)
RU (1) RU2487878C1 (da)
TR (1) TR201901561T4 (da)
WO (1) WO2013172732A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626954C2 (ru) * 2015-11-11 2017-08-02 Общество С Ограниченной Ответственностью "Вдс Фарма" Комплексные соединения германия с аминокислотами и липоевой кислотой
RU2752934C1 (ru) * 2020-10-16 2021-08-11 Александр Дмитриевич Исаев Комплексные соединения германия с ациклическими полиолами и способ их получения
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3616208A (en) * 1967-09-29 1971-10-26 Parke Davis & Co Fermentation process for 9-(beta-d-arabinofuranosyl)adenine
JPS4924213B1 (da) * 1969-04-02 1974-06-21
JPS4924213A (da) 1972-06-19 1974-03-04
DE3212817A1 (de) * 1982-04-06 1983-10-13 Sanum-Kehlbeck GmbH & Co KG, 2812 Hoya Pharmazeutisch wirksame organische germaniumverbindungen und verfahren zu deren herstellung
EP0477871A3 (en) 1990-09-28 1992-12-02 Nippon Kayaku Kabushiki Kaisha Antiviral composition, containing guanine derivatives
CN1154359A (zh) 1996-01-12 1997-07-16 常达正 氨基酸锗的制备方法及其应用
EP0931084B1 (en) * 1996-09-05 2002-02-06 Primamedic Limited 1,3-dicarboxylic germanium complex and its therapeutic use
RU2104032C1 (ru) * 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
AU9343298A (en) * 1998-08-17 2000-03-14 Evgeny Andreevich Chernyshev Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum
US6448227B1 (en) 1999-02-22 2002-09-10 Gernot Treusch Therapeutically effective substance mixture
RU2240792C2 (ru) 2002-07-30 2004-11-27 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского РАМН Комбинации на основе нетропсина или его бис-производного, обладающие антигерпетической активностью
RU2233280C1 (ru) 2003-03-25 2004-07-27 Научно-исследовательский институт физической и органической химии Ростовского государственного университета СОЛИ-10-ω-АРИЛОКСИАЛКИЛ-2,3,4,10-ТЕТРАГИДРОПИРИМИДО[1,2-A]БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ МЕСТНОАНЕСТЕЗИРУЮЩИМ ДЕЙСТВИЕМ
DE10343365A1 (de) 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
RU2476436C1 (ru) * 2012-01-25 2013-02-27 Общество С Ограниченной Ответственностью "Вдс Фарма" Комплексные соединения германия с аминокислотами и карбоновыми кислотами

Also Published As

Publication number Publication date
WO2013172732A1 (ru) 2013-11-21
BR112014027919B1 (pt) 2020-02-04
ES2710915T3 (es) 2019-04-29
JP2015518823A (ja) 2015-07-06
EP2851368A4 (en) 2016-02-10
CA2873390C (en) 2017-10-24
US20150126726A1 (en) 2015-05-07
CN104302651B (zh) 2017-04-12
IN2014DN09234A (da) 2015-07-10
CN104302651A (zh) 2015-01-21
AU2012380376A1 (en) 2014-12-04
KR101717280B1 (ko) 2017-03-17
RU2487878C1 (ru) 2013-07-20
KR20150011386A (ko) 2015-01-30
EP2851368A1 (en) 2015-03-25
PT2851368T (pt) 2019-02-11
BR112014027919A2 (pt) 2017-06-27
US9745337B2 (en) 2017-08-29
PL2851368T3 (pl) 2019-06-28
EP2851368B1 (en) 2019-01-02
AU2012380376B2 (en) 2015-10-01
JP5993088B2 (ja) 2016-09-14
CA2873390A1 (en) 2013-11-21
TR201901561T4 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
CN103232490A (zh) 具有抑制hiv-1/hbv病毒复制活性的核苷类化合物、制备方法及抗病毒方面的应用
ES2877854T3 (es) Una sal de maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, procedimientos de fabricación y usos de las mismas para el tratamiento de los virus del herpes
DK2851368T3 (da) Kompleks-forbindelser af germanium, fremgangsmåder til fremstilling deraf, og lægemidler
JP3224395B2 (ja) ベンザミド誘導体、該誘導体を含む組成物およびその使用
Hassan et al. The potential antiviral activity of a novel pyrimidine derivative against Herpes Simplex Virus type-1 (HSV-1)
CN103347849B (zh) 富勒烯с60的均聚氨基酸和杂多氨基酸衍生物、其制备方法和基于该衍生物的药物组合物
KR20020041451A (ko) 세포내 원핵생물, ｄｎａ 바이러스 및 레트로바이러스에의한 감염을 치료하기 위한 3-히드록시-4-피론의 갈륨착물
US10266545B2 (en) Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use
US8044098B2 (en) Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection
WO2012064222A1 (ru) Средство для индукции эндогенного интерферона
WO2012091610A1 (ru) Лекарственное средство с активностью против семейства герпес-вирусов
JPS63264527A (ja) 抗エイズウイルス剤
CN105055387A (zh) 牛磺酸在制备抗病毒药物中的应用
EP3661937B1 (en) Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
HK40069164B (en) Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
CN104940176B (zh) 苦参啶的医药用途
HK40079565A (en) Cysteamine for the treatment of sars-cov-2 infection
EP4581031A1 (en) A novel crystalline form of pritelivir
HK40025637B (en) Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
HK40025637A (en) Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
CN112979705A (zh) 核苷酸类似物化合物及其盐、制备方法及其药物用途